论文部分内容阅读
目的研究MYL9在前列腺癌组织中的表达水平与前列腺癌临床预后的相关性。方法采用免疫组织化学检测80例前列腺癌根治术患者前列腺癌及61例癌旁良性前列腺组织中的MYL9的表达水平,并与前列腺癌(PCa)患者的临床特征相比较。结果在良性和前列腺癌组织中,MYL9均主要在前列腺间质而不是在前列腺上皮细胞表达,前列腺癌样本中的MYL9表达水平相对于良性前列腺组织显著下调(PCa=3.21±1.46 vs.Benign=4.63±0.97,P<0.001)并伴有肿瘤间质容积的明显减少。MYL9的下调表达与前列腺癌的Gleason评分(P<0.001)明显相关。结论表明MYL9表达下调越明显,则前列腺癌患者临床预后越差。该研究为MYL9在前列腺癌组织中的下调表达可作为预测人类前列腺癌患者的不良临床预后的指标提供了证据。
Objective To investigate the correlation between the expression of MYL9 in prostate cancer and the clinical prognosis of prostate cancer. Methods Immunohistochemistry was used to detect the expression of MYL9 in 80 cases of prostate cancer and 61 cases of paracancerous benign prostate tissue and compared with the clinical features of patients with prostate cancer (PCa). Results MYL9 was mainly expressed in prostate stroma rather than prostate epithelium in both benign and prostatic cancer tissues, and MYL9 expression was significantly downregulated in prostate cancer specimens relative to benign prostatic tissue (PCa = 3.21 ± 1.46 vs. Benign = 4.63 ± 0.97, P <0.001) with a significant reduction of tumor interstitial volume. The down-regulated expression of MYL9 was significantly associated with the Gleason score of prostate cancer (P <0.001). Conclusions show that the more obvious MYL9 down regulation, the prognosis of patients with prostate cancer worse. This study provides evidence that MYL9 downregulation in prostate cancer tissues can be used as an indicator of poor clinical prognosis in human prostate cancer patients.